Free Trial

Bausch + Lomb (BLCO) Stock Forecast & Price Target

Bausch + Lomb logo
$15.96 +0.05 (+0.28%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Bausch + Lomb - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
6
Buy
5

Based on 12 Wall Street analysts who have issued ratings for Bausch + Lomb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 12 analysts, 1 has given a sell rating, 6 have given a hold rating, and 5 have given a buy rating for BLCO.

Consensus Price Target

$20.00
25.35% Upside
According to the 12 analysts' twelve-month price targets for Bausch + Lomb, the average price target is $20.00. The highest price target for BLCO is $25.00, while the lowest price target for BLCO is $17.00. The average price target represents a forecasted upside of 25.35% from the current price of $15.96.
Get the Latest News and Ratings for BLCO and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bausch + Lomb and its competitors.

Sign Up

BLCO Analyst Ratings Over Time

TypeCurrent Forecast
3/25/24 to 3/25/25
1 Month Ago
2/24/24 to 2/23/25
3 Months Ago
12/26/23 to 12/25/24
1 Year Ago
3/26/23 to 3/25/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
Hold
6 Hold rating(s)
7 Hold rating(s)
7 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$20.00$19.83$20.58$19.68
Forecasted Upside25.35% Upside25.97% Upside15.25% Upside18.46% Upside
Consensus Rating
Hold
Hold
Hold
Moderate Buy
Remove Ads

BLCO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BLCO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bausch + Lomb Stock vs. The Competition

TypeBausch + LombMedical CompaniesS&P 500
Consensus Rating Score
2.33
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside25.72% Upside21,107.26% Upside16.93% Upside
News Sentiment Rating
Positive News

See Recent BLCO News
Positive News
Positive News
Remove Ads
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
2/20/2025Royal Bank of Canada
4 of 5 stars
Douglas Miehm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOutperform ➝ Outperform$22.00 ➝ $18.00+11.77%
2/20/2025Needham & Company LLC
2 of 5 stars
David Saxon
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
2/20/2025Bank of America
3 of 5 stars
Craig Bijou
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetUnderperform ➝ Underperform$18.00 ➝ $17.00+4.39%
2/18/2025HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Yi Chen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$23.00 ➝ $23.00+39.93%
1/29/2025Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Thomas Stephan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetHold ➝ Hold$19.00 ➝ $18.00+3.42%
1/16/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Larry Biegelsen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetOverweight ➝ Overweight$26.00 ➝ $24.00+39.45%
12/11/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Wuensch
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$24.00 ➝ $22.00+6.43%
12/2/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$19.00-4.14%
10/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
V. Kumar
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeIn-Line ➝ Outperform$19.00 ➝ $25.00+19.90%
8/1/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$14.00 ➝ $18.00+4.05%
8/1/2024Evercore
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetIn-Line$15.50 ➝ $17.00-1.85%
7/10/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Nachman
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$19.00+23.94%
2/26/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$17.00 ➝ $18.00+2.27%
8/3/2023Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$22.00 ➝ $25.00+34.48%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 10:45 AM ET.


BLCO Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Bausch + Lomb is $20.00, with a high forecast of $25.00 and a low forecast of $17.00.

12 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bausch + Lomb in the last twelve months. There is currently 1 sell rating, 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" BLCO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLCO, but not buy additional shares or sell existing shares.

According to analysts, Bausch + Lomb's stock has a predicted upside of 25.35% based on their 12-month stock forecasts.

Bausch + Lomb has been rated by research analysts at Bank of America, HC Wainwright, Needham & Company LLC, Royal Bank of Canada, Stifel Nicolaus, and Wells Fargo & Company in the past 90 days.

Analysts like Bausch + Lomb less than other "medical" companies. The consensus rating for Bausch + Lomb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BLCO compares to other companies.


This page (NYSE:BLCO) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners